

Financial news for IPXL dated on 2018-05-02: S&P Dow Jones Indices Announces 'Apergy Set to Join S&P MidCap 400; 3D Systems to Join S&P SmallCap 600'

Financial news for IPXL dated on 2018-05-02: Barclays: Impax Labs-Amneal Pharma Merger Creates A Generics Leader

Financial news for IPXL dated on 2018-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2018

Financial news for IPXL dated on 2018-05-01: Barclays Initiates Coverage On Impax Laboratories with Overweight Rating, Announces \$27.00 Price Target

Financial news for IPXL dated on 2018-04-30: Amneal And Impax Late Friday Received FTC Clearance For Business Combination

Financial news for IPXL dated on 2018-04-06: Impax Launches a Generic Version of Estrace Cream

Financial news for IPXL dated on 2018-03-27: Impax Labs Reports Holders Have Approved Deal With Amneal

Financial news for IPXL dated on 2018-03-07: Benzinga's Top Upgrades, Downgrades For March 7, 2018

Financial news for IPXL dated on 2018-03-07: SunTrust Robinson Humphrey Initiates Coverage On Impax Laboratories with Buy Rating, Announces \$24.00 Price Target

Financial news for IPXL dated on 2018-03-01: Impax Reports Q4 EPS \$0.11 vs \$0.11 Est., Sales \$182.9M vs \$198M Est.

Financial news for IPXL dated on 2018-02-20: Impax Announces the Launch of Generic Solodyn

Financial news for IPXL dated on 2018-01-30: Impax Laboratories Sells CorePharma To A Group Of Industry Investors, No Terms Disclosed

Financial news for IPXL dated on 2018-01-11: Cantor Out With Note On Endo, Says Oxyomphone Subpoena May Not Hurt That Much And Is Isolated To Endo For Now, But More Co.'s Could Be The Target To Investigations Over Time Including Teva, Mylan, Impax, Mallinckrodt, Allergan

Financial news for IPXL dated on 2018-01-02: Leerink Initiates Coverage On Impax Laboratories with Outperform Rating, Announces \$22.00 Price Target

Financial news for IPXL dated on 2017-12-19: Impax Labs Reports Sale Of Taiwan Manufacturing Facility For \$18.5M

Financial news for IPXL dated on 2017-12-15: Cantor Out Positive On Impax, Says Amneal's Approval Of Triamcinolone Acetonide Injection Bridges Gap Between Co.'s Guidance For Acquisition Of Amneal And Sales Trends Over First 9 Mo. For Both Comanches, Says This Has Been An Overhand On Stock

Financial news for IPXL dated on 2017-12-08: Impax Labs Reports Received Tentative FDA Approval Of Generic Coreg CR ER Capsules

Financial news for IPXL dated on 2017-11-10: Cantor Fitzgerald Maintains Overweight on Impax Laboratories, Raises Price Target to \$35.00

Financial news for IPXL dated on 2017-11-09: Impax Reports Q3 EPS \$0.23 vs \$0.20 Est., Sales \$206.4M vs \$209.6M Est.

Financial news for IPXL dated on 2017-11-09: Impax Narrows FY17 Adj. EPS Outlook From \$0.55-\$0.70 To \$0.60-\$0.65 vs \$0.70 Est.

Financial news for IPXL dated on 2017-11-09: Impax Labs Reports Q3 Adj. EPS \$0.23 vs \$0.20 Est., Sales \$206M vs \$209.6M Est.

Financial news for IPXL dated on 2017-11-09: Earnings Scheduled For November 9, 2017

Financial news for IPXL dated on 2017-10-23: Impax Says Sales Of Generic Renvela Included In Co.'s Previously-Issued FY17 EPS Outlook Of \$0.55-\$0.70

Financial news for IPXL dated on 2017-10-23: Impax Labs Reports FDA Approval, Launch Of Generic Renvela Tablets, 800 mg

Financial news for IPXL dated on 2017-10-18: Wall Street's M&A Chatter From October 17: Sinclair, Impax Labs, WePay, Splunk-SignalSense

Financial news for IPXL dated on 2017-10-17: 30 Stocks Moving In Tuesday's Mid-Day

Session

Financial news for IPXL dated on 2017-10-17: Mid-Day Market Update: Syntel Surges After Strong Q3 Results; Impax Laboratories Shares Drop

Financial news for IPXL dated on 2017-10-17: Mid-Morning Market Update: Markets Edge Higher; Goldman Sachs Beats Q3 Expectations

Financial news for IPXL dated on 2017-10-17: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IPXL dated on 2017-10-17: Wall Street's M&A Chatter From October 16: Ruby Tuesday, Nordstrom, Aramark-Avendra, Impax-Amneal

Financial news for IPXL dated on 2017-10-17: Impax Labs to Resume Trading at 8am EDT

Financial news for IPXL dated on 2017-10-17: Impax Labs and Amneal Pharma to Merge in an All Stock Transaction, Impax Shareholders to Own 25% of the Combined Company

Financial news for IPXL dated on 2017-10-17: Impax Labs Halted, News Pending

Financial news for IPXL dated on 2017-10-16: Impax Laboratories and Amneal Pharma Reportedly Near Merger Agreement

Financial news for IPXL dated on 2017-09-28: Noticing Weakness In Several Generic Names Thurs.: Impax Labs Down 8%, Lannett Shares Down 4.4%; Not Seeing Any News To Justify Price Action; However, Lannett Shares Were Up 9% On Wed. Amid FDA Approval For Oxycodone, Acetaminophen Tablets

Financial news for IPXL dated on 2017-09-28: Goldman Sachs Initiates Coverage On Impax Laboratories with Neutral Rating, Announces \$20.00 Price Target

Financial news for IPXL dated on 2017-09-21: Dow Jones Reports Impax Laboratories Is In Talks To Combine With Amneal Pharmaceuticals, Could Reach Deal Next Month And Report Says Typical Premium Could Value Impax At \$2B Or More

Financial news for IPXL dated on 2017-08-31: Mid-Afternoon Market Update: Shoe Carnival Climbs On Upbeat Earnings; Genesco Shares Drop

Financial news for IPXL dated on 2017-08-31: 18 Biggest Mid-Day Gainers For Thursday

Financial news for IPXL dated on 2017-08-31: Mid-Day Market Update: Crude Oil Up 2.5%; DryShips Shares Decline On News Of SEC Subpoena

Financial news for IPXL dated on 2017-08-31: Mid-Morning Market Update: Markets Open Higher; Dollar General Tops Q2 Views

Financial news for IPXL dated on 2017-08-14: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for IPXL dated on 2017-08-09: 20 Biggest Mid-Day Gainers For Wednesday

Financial news for IPXL dated on 2017-08-09: Impax Reaffirms FY 2017 EPS Guidance

Financial news for IPXL dated on 2017-08-09: Impax Q2 Adj. EPS \$0.18 vs \$0.14 Est., Sales \$202.1M vs \$195.6M Est.

Financial news for IPXL dated on 2017-08-07: Impax Labs Announces Settlement for Endo International Contract Dispute, Impax to Pay Endo a Royalty on Oxymorphone Hydrochloride Products Starting Jan 1, 2018

Financial news for IPXL dated on 2017-07-31: 15 Biggest Mid-Day Losers For Monday

Financial news for IPXL dated on 2017-07-31: Benzinga's Top Upgrades, Downgrades For July 31, 2017

Financial news for IPXL dated on 2017-07-31: Canaccord Genuity Initiates Coverage On Impax Laboratories with Hold Rating, Announces \$19.00 Price Target

Financial news for IPXL dated on 2017-07-26: Four Stocks Breaking Out

Financial news for IPXL dated on 2017-07-18: Benzinga's Top Upgrades, Downgrades For July 18, 2017

Financial news for IPXL dated on 2017-07-18: PiperJaffray Upgrades Impax Laboratories to Neutral

Financial news for IPXL dated on 2017-07-17: Impax Labs Gets FDA Approval on its ANDA for Generic Concerta

Financial news for IPXL dated on 2017-07-05: Impax Announces FDA Approval Of Generic Focalin XR

Financial news for IPXL dated on 2017-06-22: Turing Board Could Appoint Founder Martin Shkreli As CEO Or Chairman, But He Has No Interest

Financial news for IPXL dated on 2017-06-16: Cantor Fitzgerald Initiates Coverage On Impax Laboratories with Overweight Rating, Announces \$20.00 Price Target

Financial news for IPXL dated on 2017-05-10: Turing Rejects \$100 Million Offer For Daraprim

Financial news for IPXL dated on 2017-04-26: Impax Reports FDA Approval and Launch of a Generic Version of Vytorin

Financial news for IPXL dated on 2017-04-24: Vetr Crowd Urges Sell For Impax Laboratories

Financial news for IPXL dated on 2017-03-30: Impax Reports Favorable Ruling Regarding Patent Validity for Zomig Nasal Spray

Financial news for IPXL dated on 2017-03-27: Mid-Afternoon Market Update: Silver Futures Up 2%; Foamix Pharma Shares Plummet

Financial news for IPXL dated on 2017-03-27: 15 Biggest Mid-Day Gainers For Monday

Financial news for IPXL dated on 2017-03-27: Mid-Day Market Update: Dow Falls 80 Points; Collect Biotechnology Shares Spike Higher

Financial news for IPXL dated on 2017-03-27: Mid-Morning Market Update: Markets Open Lower; G-III Apparel Misses Q4 Views

Financial news for IPXL dated on 2017-03-27: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for IPXL dated on 2017-03-27: Impax Names Paul Bisaro CEO

Financial news for IPXL dated on 2017-03-08: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for IPXL dated on 2017-03-08: Benzinga's Top Upgrades, Downgrades For March 8, 2017

Financial news for IPXL dated on 2017-03-08: Susquehanna Downgrades Impax Laboratories To Neutral, Lowers Price Target To \$10

Financial news for IPXL dated on 2017-03-08: More Pros Than Cons Investing In Impax Right Now

Financial news for IPXL dated on 2017-03-08: Wall Street's M&A Chatter From March 7

Financial news for IPXL dated on 2017-03-08: Deutsche Bank Upgrades Impax Laboratories To Buy, Maintains \$11 Price Target

Financial news for IPXL dated on 2017-03-07: Impax Labs Working with Morgan Stanley on Strategic Review -Reuters

Financial news for IPXL dated on 2017-03-07: Reuters Reporting Impax Laboratories Working With Morgan Stanley On Strategic Review

Financial news for IPXL dated on 2017-03-01: Mid-Afternoon Market Update: Weight Watchers Rises On Upbeat Earnings; Babcock & Wilcox Shares Drop

Financial news for IPXL dated on 2017-03-01: 18 Biggest Mid-Day Losers For Wednesday

Financial news for IPXL dated on 2017-03-01: Mid-Day Market Update: Dow Rises Over 250 Points; Palo Alto Shares Plunge

Financial news for IPXL dated on 2017-03-01: Mid-Morning Market Update: Markets Open Higher; Best Buy Sales Miss Views

Financial news for IPXL dated on 2017-03-01: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for IPXL dated on 2017-03-01: Impax Labs Reports Q4 Adj. EPS \$0.16, Inline, Sales \$198.4M vs \$219.3M Est.

Financial news for IPXL dated on 2017-03-01: Earnings Scheduled For March 1, 2017

Financial news for IPXL dated on 2017-01-27: Evercore Out With Color On Mylan, Says EpiPen Competitors Appear To Be Having An Impact, Specifically Impax

Financial news for IPXL dated on 2017-01-23: FTC Keeps Pressure On Wall Street, Refiles Suit Against Allergan, Others

Financial news for IPXL dated on 2017-01-23: FTC Refiles Suits Against Allergan For Blocking Lower-Cost Generic Version Of Painkiller Lidoderm, FTC Issues Administrative Complaint Against Impax Lab For Similar Scheme With Regard To Opana ER

Financial news for IPXL dated on 2017-01-06: Impax Reports Confirmation of Patent Challenge Related to Generic Aubagio Tablets, 14 mg

Financial news for IPXL dated on 2017-01-06: Impax Confirms Patent Challenge Relating to Generic Aubagio (teriflunomide) Tablets, 14 mg

Financial news for IPXL dated on 2016-12-28: Benzinga's Top Upgrades, Downgrades For December 28, 2016

Financial news for IPXL dated on 2016-12-28: The Market In 5 Minutes: Redbook Retail Sales Higher Across The Board

Financial news for IPXL dated on 2016-12-28: Janney Capital Initiates Coverage On Impax Laboratories at Neutral, Announces \$15.00 Target

Financial news for IPXL dated on 2016-12-22: UPDATE: Deutsche Bank's Gilbert on Impax: Questions 'Time to explore strategic options?'; Highlights Sum-of-the-Parts Analysis Suggests Upside Potential in Sale Scenario, Sees Median Deal Multiples Yielding Theoretical Value of \$22-\$41/Share

Financial news for IPXL dated on 2016-12-22: Impax Shares Volatile Here as Traders Passing Around Unconfirmed Chatter of Vague Discussion from Deutsche Bank Analyst

Financial news for IPXL dated on 2016-12-22: Impax Launches Generic Version of Kadian

Financial news for IPXL dated on 2016-12-20: Impax Laboratories Names J. Kevin Buchi Interim President and CEO, Board Commences Search For Permanent CEO

Financial news for IPXL dated on 2016-12-14: First Charges Filed in Generic Drug Price Probe: Connected Stocks Sell Off

Financial news for IPXL dated on 2016-12-14: Weakness in Several Pharma Names Being Attributed to Bloomberg Report Lannett, Impax, Endo, Taro, Actavis, Covis, Sun Pharma, Mayne Received Subpoenas

Financial news for IPXL dated on 2016-11-14: Wallachbeth Downgrades Impax Laboratories, Inc. - Common Stock to Hold

Financial news for IPXL dated on 2016-11-09: Mid-Afternoon Market Update: Dow Climbs 250 Points; Impax Labs Shares Down Following Q3 Results

Financial news for IPXL dated on 2016-11-09: 20 Biggest Mid-Day Losers For Wednesday

Financial news for IPXL dated on 2016-11-09: Impax Lowers Guidance; Sees FY 2016 EPS \$1.10 to \$1.20 vs Prior \$1.57 to \$1.70 Est; Revenue \$840M to \$855M vs Prior \$900M to \$940M Est

Financial news for IPXL dated on 2016-11-09: Impax Q3 EPS \$0.37 vs \$0.39 Est, Revenue \$227.9M vs \$234.8M Est

Financial news for IPXL dated on 2016-11-09: Earnings Scheduled For November 9, 2016

Financial news for IPXL dated on 2016-11-07: Impax Labs Needs A Lot To Go Right To Meet Its Earnings Goals

Financial news for IPXL dated on 2016-11-07: Bank of America Downgrades Impax Laboratories, Inc. - Common Stock to Underperform

Financial news for IPXL dated on 2016-11-04: Despite Department Of Justice Investigation, Now May Be The Time To Buy Generic Drug Stocks

Financial news for IPXL dated on 2016-11-03: Hearing Dept. of Justice is Probing Generic Cos., Mylan, Teva, Actavis, Impax, Endo's Par, Covis, Lannett, Others Received Subpoenas

Financial news for IPXL dated on 2016-10-24: Goldman Says These 25 Healthcare Stocks Are Immune To The Election

Financial news for IPXL dated on 2016-09-27: Heightened Drug Pricing Scrutiny Now A

Factor In Analysts Views Of Impax Labs, Concordia International

Financial news for IPXL dated on 2016-09-27: Goldman Sachs Upgrades Impax Laboratories to Neutral, Raises PT to \$26.00

Financial news for IPXL dated on 2016-09-22: Impax Reports Launch of Generic Metadate CD E-R Capsules

Financial news for IPXL dated on 2016-08-30: Impax Provides Update on Epinephrine Injection, USP Auto-Injector, CEO Highlights Auto-Injector Low Cost Treatment For Patient Who Require Epinephrine Products

Financial news for IPXL dated on 2016-08-26: Mylan Is Offering An EpiPen Savings Card, But A Lot Of People Will Still Get Screwed

Financial news for IPXL dated on 2016-08-24: Social Sentiment On Mylan Is Nearly Unanimously Negative, And Could Benefit A Competitor

Financial news for IPXL dated on 2016-08-24: A Cheaper Option To The EpiPen

Financial news for IPXL dated on 2016-08-24: Drug Price Hike Concerns Spill Over Into Other Pharma Stocks

Financial news for IPXL dated on 2016-08-24: Mallinckrodt, Impax Labs Shares Plunge Over This Afternoon's Session; Traders May Be Viewing These Names as Plays on the Drug Price Increase Debate

Financial news for IPXL dated on 2016-08-15: Northland Securities Upgrades Impax Laboratories to Outperform

Financial news for IPXL dated on 2016-08-09: Tuesday's Market Wrap: Stocks Little Changed Once Again

Financial news for IPXL dated on 2016-08-09: Mid-Afternoon Market Update: Endo Rises On Earnings Beat; Impax Laboratories Shares Slide

Financial news for IPXL dated on 2016-08-09: 20 Biggest Mid-Day Losers For Tuesday

Financial news for IPXL dated on 2016-08-09: Stocks Hitting 52-Week Lows

Financial news for IPXL dated on 2016-08-09: Impax Raises FY16 Guidance \$900-\$940M vs. Est. \$994M, EPS Of \$1.57-\$1.70 vs. Est. \$1.77

Financial news for IPXL dated on 2016-08-09: Impax Reports Q2 EPS \$0.21 vs. Est. \$0.32, Rev. \$172.6M vs. Est. \$223.6M

Financial news for IPXL dated on 2016-06-29: BMO Capital Initiates Coverage on Impax Laboratories at Market Perform

Financial news for IPXL dated on 2016-06-21: Benzinga's M&A Chatter for Tuesday June 21, 2016

Financial news for IPXL dated on 2016-06-21: Bank of America Upgrades Impax Laboratories to Neutral

Financial news for IPXL dated on 2016-06-21: 8 Biggest Mid-Day Losers For Tuesday

Financial news for IPXL dated on 2016-06-21: The Market In 5 Minutes: #TrumpSoPoor And More

Financial news for IPXL dated on 2016-06-21: Impax Agrees To Buy Genetic Products For \$586 Million

Financial news for IPXL dated on 2016-06-21: Impax Laboratories And Teva Agreed To Terminate All Rights, Obligations Of Each Party With Respect To Methylphenidate HCL ER

Financial news for IPXL dated on 2016-06-21: UPDATE: Impax Sees FY16 Sales Growth At Least 15%, CapEx ~\$40M

Financial news for IPXL dated on 2016-06-21: Impax Labs Raises FY16 Adj. EPS Outlook from At Least 10% YoY Growth to At Least 20% Growth

Financial news for IPXL dated on 2016-06-21: UPDATE: Impax To Add These Generics Upon Closing Of The Deal, See Body

Financial news for IPXL dated on 2016-06-21: UPDATE: Impax Deal Signifies Return Of Impax To Its Generic Equivalent To Concerta For \$586M

Financial news for IPXL dated on 2016-06-21: Impax Reports Deal to Buy Generic Products from Teva, Affiliates of Allergan for \$586M

Financial news for IPXL dated on 2016-06-06: Goldman Initiates Specialty Pharma At Neutral, Highlights 'A Confluence Of Concerns'

Financial news for IPXL dated on 2016-06-06: Goldman Initiates Impax Labs With Sell Rating, \$33 Target

Financial news for IPXL dated on 2016-06-06: Goldman Sachs Initiates Coverage on Impax Laboratories at Sell, Announces \$33.00 PT

Financial news for IPXL dated on 2016-05-10: Impax Q1 EPS \$0.43 vs \$0.39 est, Revenue \$225.5M vs \$247.2M est

Financial news for IPXL dated on 2016-04-19: Northland Securities Initiates Coverage on Impax Laboratories at Market Perform

Financial news for IPXL dated on 2016-04-13: Impax Reports Availability of EMVERM

Financial news for IPXL dated on 2016-03-09: Impax Labs Reports Civil Investigative Demand from the U.S. Attorney Office, Southern District of New York, Civil Frauds Unit

Financial news for IPXL dated on 2016-03-09: Impax Labs Announces Closure of New Jersey Packaging Site

Financial news for IPXL dated on 2016-02-22: Impax Labs Sees EPS Up 10% and Revenue Up 15% in 2016

Financial news for IPXL dated on 2016-02-22: Impax Labs Q4 EPS \$0.62 vs \$0.44 est, Revenue \$282.1M vs \$222.8M est

Financial news for IPXL dated on 2016-02-22: Earnings Scheduled For February 22, 2016

Financial news for IPXL dated on 2016-02-17: Earlier Raymond James Upgraded Impax Laboratories to Market Perform

Financial news for IPXL dated on 2016-02-17: Impax Receives FDA Approval for Generic Version of Adderall XR Capsules, CII; IMS Health Says U.S. Market Was \$1.8B For 12 Mo. As Of Nov. 2015

Financial news for IPXL dated on 2016-02-02: Impax Labs Reports Tentative FDA Approval for Generic Version of Vytorin Tablets, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg

Financial news for IPXL dated on 2016-01-15: Impax Labs Announces FDA Approval for Chewable Tablets

Financial news for IPXL dated on 2016-01-06: Benzinga's Top Initiations

Financial news for IPXL dated on 2016-01-06: JP Morgan Initiates Coverage on Impax Laboratories at Neutral, Announces \$47.00 PT

Financial news for IPXL dated on 2015-12-11: Piper Jaffray's David Amsellem on Impax's Generics Unit Heading Into '16, Says 'Staying Bullish'; Overweight Rating, \$50 Target Reiterated

Financial news for IPXL dated on 2015-11-25: Impax Labs Reports Receiving of EC Marketing Authorization for NUMIENT Modified-Release Caps for Symptomatic Treatment of Patients with Parkinson's

Financial news for IPXL dated on 2015-11-16: Tiger Global Liquidates Impax Labs Stake

Financial news for IPXL dated on 2015-11-09: Impax Reports Q3 EPS \$0.40 vs. Est. \$0.39, Rev. \$221M vs. Est. \$214.45M

Financial news for IPXL dated on 2015-10-21: Impax Receives FDA Approval for Generic Version of Intuniv Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg

Financial news for IPXL dated on 2015-10-08: Janet S. Vergis Appointed to Impax Laboratories Board of Directors

Financial news for IPXL dated on 2015-10-05: US Stock Futures Rise Ahead Of Economic Data

Financial news for IPXL dated on 2015-10-05: Impax Receives FDA Approval for Generic Version of DIABETA Tablets, USP, 1.25 mg, 2.5 mg, and 5 mg

Financial news for IPXL dated on 2015-10-05: Impax Receives FDA Approval for Generic Version of DIABETA(r) (Glyburide) Tablets, USP, 1.25 mg, 2.5 mg, and 5 mg

Financial news for IPXL dated on 2015-09-22: US Stock Futures Signal Lower Start On Wall Street

Financial news for IPXL dated on 2015-09-22: Impax Receives FDA Approval for Generic Version of Testred(r) C-III (Methyltestosterone Capsules, USP), 10 mg

Financial news for IPXL dated on 2015-09-22: Impax Announces FDA Approval for Generic Version of Testred C-III, 10 mg

Financial news for IPXL dated on 2015-09-17: Impax Announces FDA Approval For Generic Mestinon Timespan

Financial news for IPXL dated on 2015-09-08: Impax Labs Has Resolved Issues With FDA at Hayward Manufacturing Facility According to Company Letter

Financial news for IPXL dated on 2015-08-20: The Coming Drug-Patent Cliff Is Pushing This Portfolio Up

Financial news for IPXL dated on 2015-08-14: Impax Labs Spikes Higher

Financial news for IPXL dated on 2015-08-11: 5 Biotechs Leerink Analysts Are Watching

Financial news for IPXL dated on 2015-08-10: US Stock Futures Signal Higher Start On Wall Street

Financial news for IPXL dated on 2015-08-10: Impax Labs Reports Q2 Adj EPS \$0.34 Vs est \$0.35, Sales \$214.2M Vs Est \$199.96M

Financial news for IPXL dated on 2015-08-10: Impax Announces Sale of Daraprim to Turing Pharmaceuticals AG , ~\$55M

Financial news for IPXL dated on 2015-08-10: Earnings Scheduled For August 10, 2015

Financial news for IPXL dated on 2015-07-28: ETFs For The Next Pharma Takeover Candidates

Financial news for IPXL dated on 2015-07-21: Susquehanna Initiates Coverage on Impax Laboratories at Positive, Announces \$60.00 PT

Financial news for IPXL dated on 2015-07-20: Susquehanna Initiates Coverage on Impax Laboratories at Positive, Announces \$60.00 PT

Financial news for IPXL dated on 2015-06-25: Keep An Eye On These 10 After-Hours Movers

Financial news for IPXL dated on 2015-06-16: FDA Approves ZOMIG(r) (zolmitriptan) Nasal Spray for Migraine in Pediatric Patients (Ages 12-17)

Financial news for IPXL dated on 2015-06-03: Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Financial news for IPXL dated on 2015-06-03: Raymond James Initiates Coverage on Impax Laboratories at Underperform

Financial news for IPXL dated on 2015-05-29: Who's The Next Big Pharma Acquisition?

Financial news for IPXL dated on 2015-05-13: 5 New Biotech Developments Worth Watching

Financial news for IPXL dated on 2015-05-11: Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers

Financial news for IPXL dated on 2015-05-11: Impax Labs Earlier Announced FDA Performed GMP, Pre-Approval Inspection of Co.'s Hayward Plant: Found Added Items Co. Will Need to Focus On, Co. to Respond Within 15 Days of Form 483 Receipt

Financial news for IPXL dated on 2015-05-11: Impax Labs Reports Q1 Adj EPS \$0.09 vs Est \$0.18 May Not Compare, Revs \$143.1M vs Est \$146.13M

Financial news for IPXL dated on 2015-04-17: UBS Says Impax 'Ahead Of Itself,' Downgrades To Sell

Financial news for IPXL dated on 2015-04-17: Benzinga's Top Downgrades

Financial news for IPXL dated on 2015-04-17: UBS Downgrades Impax Laboratories To Sell

Financial news for IPXL dated on 2015-04-17: UBS Downgrades Impax Laboratories to Sell

Financial news for IPXL dated on 2015-04-08: 2 Biotech Stocks Deutsche Bank Just Initiated

Financial news for IPXL dated on 2015-04-07: Deutsche Bank Initiates Coverage on Impax Laboratories at Hold, Announces \$50.00 PT

Financial news for IPXL dated on 2015-03-11: Piper Jaffray Upgrades Impax Laboratories to Overweight

Financial news for IPXL dated on 2015-03-10: Impax Closes Purchase of Tower Holdings, Lineage Therapeutics; Sees FY15 Adj. Gross Margins as Percent of Total Sales in the Mid 50% Range, Sees CapEx ~\$45M-\$50M

Financial news for IPXL dated on 2015-03-06: FTC Requires Divestitures in Connection With Impax Laboratories Inc.'s Proposed Acquisition of CorePharma, LLC

Financial news for IPXL dated on 2015-02-25: JPM Securities Picks Through Biotech News For Winners

Financial news for IPXL dated on 2015-02-24: Impax Labs Reports Q4 Adj EPS \$0.16 Vs Est \$0.12, Sales \$131.2M Vs Est \$125.47M

Financial news for IPXL dated on 2015-02-24: Earnings Scheduled For February 24, 2015

Financial news for IPXL dated on 2015-02-12: impax Laboratories Says Received Three Civil Investigative Demands from Office of Alsask AG for Investigations of Drugs

Financial news for IPXL dated on 2015-02-11: Benzinga's Top Downgrades

Financial news for IPXL dated on 2015-02-11: Goldman Sachs Downgrades Impax Laboratories To Neutral

Financial news for IPXL dated on 2015-02-11: Impax Labs Downgraded From Buy to Neutral at Goldmansachs, Raises PT From \$33 to \$41

Financial news for IPXL dated on 2015-02-11: Goldman Sachs Downgrades Impax Laboratories to Neutral, Raises PT to \$41.00

Financial news for IPXL dated on 2015-02-09: Will Cisco Surprise?

Financial news for IPXL dated on 2015-02-04: Pfizer Just Won With This Breast Cancer Drug

Financial news for IPXL dated on 2015-01-26: UPDATE: Impax Announces FDA Approved Generic Version of Lamictal

Financial news for IPXL dated on 2015-01-26: Impax Announces FDA Approved Generic Version of Lamictal

Financial news for IPXL dated on 2015-01-13: 8-K from Impax Labs Offers Slideshow Presentation Ahead of JPMorgan Healthcare Conference

Financial news for IPXL dated on 2015-01-08: Stocks Hitting 52-Week Highs

Financial news for IPXL dated on 2015-01-08: Morning Market Gainers

Financial news for IPXL dated on 2015-01-08: Impax Reports FDA Approval of RYTARY ER-Capsules for Treatment of Parkinson's Disease

Financial news for IPXL dated on 2014-12-29: Impax Laboratories Says on December 24, 2014, Company Received Second Request for Additional Information and Documentary Material from FTC in Connection With Review of Tower and Lineage Acquisition -8-K

Financial news for IPXL dated on 2014-11-06: 8 Attractive U.S. Healthcare Stocks With Low PEG Ratios

Financial news for IPXL dated on 2014-11-06: Impax Submits Marketing Authorization Application to EMA for IPX066 (Carbidopa-Levodopa) Extended-Release Capsules

Financial news for IPXL dated on 2014-11-05: Piper Jaffray Downgrades Impax Laboratories, Inc. to Neutral

Financial news for IPXL dated on 2014-11-04: Impax Laboratories, Inc. Reports Q3 EPS of \$0.33 vs \$0.31 Est; Revenue of \$158.0M vs \$148.36M Est

Financial news for IPXL dated on 2014-10-24: 8-K from Impax Labs Shows Global Pharma Unit's Pres Carole Ben-Maimon to Retire

Financial news for IPXL dated on 2014-10-22: Impax Announces Departure of Carole Ben-Maimon, M.D., President of Global Pharmaceuticals

Financial news for IPXL dated on 2014-10-22: Benzinga's Top Initiations

Financial news for IPXL dated on 2014-10-22: JMP Securities Initiates Impax Laboratories With Outperform

Financial news for IPXL dated on 2014-10-22: JMP Securities Initiates Coverage on Impax Laboratories, Inc. at Outperform, Announces \$38.00 PT

Financial news for IPXL dated on 2014-10-10: Needham Upgrades Impax Laboratories, Inc. to Buy

Financial news for IPXL dated on 2014-10-09: Dow Suffers Worst One-Day Performance In 2014, Volatility Returns To The Markets

Financial news for IPXL dated on 2014-10-09: RoundTable Healthcare Partners Announces Sale Of Tower Holdings, Inc. And Lineage Therapeutics Inc. To Impax Laboratories, Inc.

Financial news for IPXL dated on 2014-10-09: Markets Drop; PepsiCo Earnings Top Estimates

Financial news for IPXL dated on 2014-10-09: Morning Market Movers

Financial news for IPXL dated on 2014-10-09: US Stock Futures Mixed Ahead Of Jobless Claims Data

Financial news for IPXL dated on 2014-10-09: UPDATE: Impax Labs to Acquire Tower Holdings, Lineage Therapeutics for \$700M in Cash

Financial news for IPXL dated on 2014-10-09: Impax to Acquire Tower Holdings, Lineage Therapeutics

Financial news for IPXL dated on 2014-09-24: Impax Labs 8-K Says Company Will Pay \$8M To Settle Class Action Suit

Financial news for IPXL dated on 2014-09-17: Impax Pharmaceuticals Announces Extension of RYTARY FDA Review Date To January 9, 2015

Financial news for IPXL dated on 2014-09-05: Option Alert: Impax Labs Shares Move Higher; Activity in Oct \$25 Call

Financial news for IPXL dated on 2014-08-06: Impax Laboratories, Inc. Reports Q2 EPS of \$0.60 Which May Not Compare \$0.37 Est; Revenue of \$188.12M Which May Not Compare \$155.97M Est

Financial news for IPXL dated on 2014-08-04: Indexes Reverse Losses; Michael Kors Beats Expectations Again

Financial news for IPXL dated on 2014-08-04: Alere Drops On Downbeat Results; Trex Shares Surge

Financial news for IPXL dated on 2014-08-04: Markets Open Higher; Michael Kors Results Beat Street View

Financial news for IPXL dated on 2014-08-04: Morning Market Losers

Financial news for IPXL dated on 2014-08-04: Shares of Impax Labs Resume Trade, Now Down ~7%

Financial news for IPXL dated on 2014-08-04: UPDATE: Impax Reports FDA Has Performed Inspection of Co.'s Hayward Facility, Says Two Inspectional Observations Designed as Repeat

Financial news for IPXL dated on 2014-08-04: Impax Reports FDA Has Performed Inspection of Co.'s Hayward Facility, Says Two Inspectional Observations Designed as Repeat

Financial news for IPXL dated on 2014-08-04: Impax Labs Halted with News Pending

Financial news for IPXL dated on 2014-07-30: Wunderlich Earlier Downgraded Impax Laboratories, Inc. to Hold

Financial news for IPXL dated on 2014-07-29: Indices Remain Mixed; Merck Beats

Expectations

Financial news for IPXL dated on 2014-07-29: Herbalife Falls On Downbeat Results; Windstream Shares Spike Higher

Financial news for IPXL dated on 2014-07-29: Cowen & Company Downgrades Impax Laboratories, Inc. to Market Perform

Financial news for IPXL dated on 2014-07-29: Markets Open Higher; Merck Posts Upbeat Profit

Financial news for IPXL dated on 2014-07-29: UPDATE: Bank Of America Reiterates On Impax Laboratories On Rolling Forward Discount Period

Financial news for IPXL dated on 2014-07-29: Morning Market Losers

Financial news for IPXL dated on 2014-07-29: PREVIEW: Impax Laboratories to Resume Trading at 8:35 AM ET

Financial news for IPXL dated on 2014-07-29: UPDATE: FDA Issued Form 483 with 10 Inspectional Observations for Impax Taiwan Plant

Financial news for IPXL dated on 2014-07-29: UPDATE: FDA Issued Form 483 with Ten Inspectional Observations for Impax Taiwan Plant

Financial news for IPXL dated on 2014-07-29: Impax Announces FDA Has Performed Inspection of Taiwan Plant

Financial news for IPXL dated on 2014-07-29: Impax Labs Halted News Pending

Financial news for IPXL dated on 2014-07-16: Why Lannett Shares Are Down More Than 16%

Financial news for IPXL dated on 2014-07-02: Impax Announces Acquisition of Two Generic Products From Actavis, Terms Not Disclosed

Financial news for IPXL dated on 2014-06-11: Wells Fargo Initiates Coverage On The Pharmaceutical Space

Financial news for IPXL dated on 2014-06-11: Wells Fargo Initiates Coverage on Impax Laboratories, Inc. at Market Perform

Financial news for IPXL dated on 2014-06-10: Conferences/Events Scheduled for Week of Jun. 9th to Jun. 13th

Financial news for IPXL dated on 2014-06-06: Benzinga's Top Initiations

Financial news for IPXL dated on 2014-06-06: Wallachbeth Capital Initiates Coverage on Impax Laboratories, Inc. at Buy, Announces \$32.00 PT

Financial news for IPXL dated on 2014-05-12: UPDATE: Perrigo Announces FDA Approval for Generic Version of Astepro

Financial news for IPXL dated on 2014-05-07: Earlier Buckingham Research Upgraded Impax Laboratories to Neutral, Raised PT to \$26.00 On Top and Bottom Line Beats

Financial news for IPXL dated on 2014-05-01: Impax Laboratories, Inc. Reports Q1 EPS of \$0.09 vs \$0.05 Est; Revenue of \$118.70M vs \$111.18M Est

Financial news for IPXL dated on 2014-04-21: Impax Board of Directors Appoints G. Frederick Wilkinson President and CEO

Financial news for IPXL dated on 2014-04-16: UPDATE: Impax Launches Authorized Generic RENVELA

Financial news for IPXL dated on 2014-04-16: Impax Launches Authorized Generic RENVELA

Financial news for IPXL dated on 2014-04-16: Sterne Agee Initiates Coverage on Impax Laboratories, Inc. at Neutral, Announces \$25.00 PT

Financial news for IPXL dated on 2014-04-11: Impax Pharma Resubmits RYTARY Extended-Release Capsules to FDA

Financial news for IPXL dated on 2014-04-02: Impax Labs Names Jeffrey Nornhold Senior VP, Technical Operations

Financial news for IPXL dated on 2014-02-26: Form 8-K from Impax Labs Shows Received Civil Investigative Demand from FTC on Feb. 25th, Related to Opana and Generic

Equivalents

Financial news for IPXL dated on 2014-01-14: Impax Labs Guides 2014 Capex \$40M-45M

Financial news for IPXL dated on 2014-01-14: Impax Labs Sees 2014 Capex \$40-45M, Adj. Gross Margins in Low-50% Range, Sees Patent Litigation Expenses \$11-13M

Financial news for IPXL dated on 2014-01-07: Impax & Durect Sign \$63M Deal to Develop, Commercialize Eladur Pain Patch

Financial news for IPXL dated on 2014-01-06: RBC Capital Initiates Coverage on Impax Laboratories, Inc. at Sector Perform, Announces \$25.00 PT

Financial news for IPXL dated on 2013-12-16: Goldman Sachs Initiates Coverage on Impax Laboratories, Inc. at Buy, Announces \$29.00 PT

Financial news for IPXL dated on 2013-11-21: Impax Labs Launches Generic Solaraze

Financial news for IPXL dated on 2013-11-13: UPDATE: Janney Capital Markets Initiates Coverage on Impax Laboratories as The Last Mid-Cap Generics Company Standing

Financial news for IPXL dated on 2013-11-13: Janney Capital Initiates Coverage on Impax Laboratories, Inc. at Buy, Announces \$30.00 PT

Financial news for IPXL dated on 2013-11-04: Impax Laboratories, Inc. Reports Q3 EPS of \$0.25 vs \$(0.08) Est; Revenue of \$132.60M vs \$110.74M Est

Financial news for IPXL dated on 2013-08-12: Buckingham Research Downgrades Impax Laboratories, Inc. to Underperform, Maintains \$15.00 PT

Financial news for IPXL dated on 2013-08-08: Impax Laboratories, Inc. Reports Q2 EPS of \$0.23 vs \$0.04 Est; Revenue of \$129.63M vs \$120.75M Est

Financial news for IPXL dated on 2013-08-07: Mylan Loses Appeal To Sell Acne Drug Oracea, Court Says Lupin, Impax Also Infringed On Patent

Financial news for IPXL dated on 2013-07-15: Impax Laboratories Launches Authorized Generic TRILIPIX(r) Delayed Release Capsules, 45 mg and 135 mg

Financial news for IPXL dated on 2013-07-15: Impax Launches Authorized Generic TRILIPIX Delayed Release Caps, 45, 135mg

Financial news for IPXL dated on 2013-07-03: Impax Labs Confirms Patent Challenge for Generic TOVIAZ 4mg, 8mg

Financial news for IPXL dated on 2013-06-25: Mid-Afternoon Market Update: Silver Turns Red as Walter Energy Rallies

Financial news for IPXL dated on 2013-06-25: Mid-Day Market Update: Lennar Rises On Upbeat Profit, Barnes & Noble Tumbles

Financial news for IPXL dated on 2013-06-25: Dr. Larry Hsu, Impax Laboratories President and Chief Executive Officer, to Retire

Financial news for IPXL dated on 2013-06-05: UPDATE: Impax Labs Sees Annual Cost Savings of \$15M

Financial news for IPXL dated on 2013-06-05: Impax Labs Announces Workforce Reduction, Cuts 110 Jobs

Financial news for IPXL dated on 2013-05-28: CORRECTION: Impax Labs to Replace Cymer in S&P SmallCap 600

Financial news for IPXL dated on 2013-05-20: Impax Board Establishes Compliance Committee, Cites FDA Warning Letter for Hayward Site

Financial news for IPXL dated on 2013-05-17: Impax Labs Launches Authorized Generic of Zomig in US

Financial news for IPXL dated on 2013-05-01: Impax Laboratories, Inc. Reports Q1 EPS of \$0.37 vs \$0.21 Est; Revenue of \$148.50M vs \$128.85M Est

Financial news for IPXL dated on 2013-04-29: Impax, Glaxo Terminate Collaboration for IPX066

Financial news for IPXL dated on 2013-03-19: Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting

Financial news for IPXL dated on 2013-03-15: Impax Pharma to Present Data from RYTARY Phase III, Open-Laebl Extension Trials at MAAN

Financial news for IPXL dated on 2013-03-07: UBS Maintains Neutral on Impax Laboratories, Inc., Lowers PT to \$17.00

Financial news for IPXL dated on 2013-03-05: Mid-Afternoon Market Update: Dow Looks Set to Close at All-Time High, Millennial Media Stumbles

Financial news for IPXL dated on 2013-03-05: Market Wrap for Tuesday, March 5: Stocks Rally as Dow Closes at New All-Time High

Financial news for IPXL dated on 2013-03-05: UPDATE: Bank of America Cuts PO to \$17 on Impax Laboratories on Persisting FDA Issues

Financial news for IPXL dated on 2013-03-05: UPDATE: JP Morgan Cut PT on Impax Laboratories Following Disappointing FDA Results

Financial news for IPXL dated on 2013-03-05: Mid-Day Market Update: Santarus Surges On Earnings Beat, Impax Tumbles

Financial news for IPXL dated on 2013-03-05: Stocks Hitting 52-Week Lows

Financial news for IPXL dated on 2013-03-05: Morning Market Losers

Financial news for IPXL dated on 2013-03-05: Mid-Morning Market Update: Markets Spike Higher, JC Penney Drops On Stock Sale Report

Financial news for IPXL dated on 2013-03-05: JP Morgan Maintains Neutral on Impax Laboratories, Inc., Lowers PT to \$19.00

Financial news for IPXL dated on 2013-03-05: Bank of America Maintains Underperform on Impax Laboratories, Inc., Lowers PO to \$17.00

Financial news for IPXL dated on 2013-03-05: Benzinga's Top Pre-Market Losers

Financial news for IPXL dated on 2013-03-05: UPDATE: Canaccord Genuity Downgrades Impax Laboratories to Hold Following FDA Warning Letter

Financial news for IPXL dated on 2013-03-05: Benzinga's Top Downgrades

Financial news for IPXL dated on 2013-03-05: Canaccord Genuity Downgrades Impax Laboratories, Inc. to Hold, Lowers PT to \$20.00

Financial news for IPXL dated on 2013-03-04: IPXL Trading Resumed

Financial news for IPXL dated on 2013-03-04: IMPAX Shares to Resume Trading at 4:40PM EST

Financial news for IPXL dated on 2013-03-04: Impax Provides an Update on FDA Inspection of Hayward Facility

Financial news for IPXL dated on 2013-03-04: Impax Labs Halted News Pending

Financial news for IPXL dated on 2013-02-26: UPDATE: Piper Jaffray Cuts PT to \$27 on Impax Laboratories on Rytary Launch Visibility

Financial news for IPXL dated on 2013-02-26: Piper Jaffray Maintains Overweight on Impax Laboratories, Inc., Lowers PT to \$27.00

Financial news for IPXL dated on 2013-02-25: Impax Laboratories, Inc. Reports Q4 EPS of \$0.23 vs \$0.19 Est; Revenue of \$141.08M vs \$126.39M Est

Financial news for IPXL dated on 2013-02-08: Shire, Impax Settle Litigation Related to Supply of Adderall XR Authorized Generic

Financial news for IPXL dated on 2013-01-22: Mid-Afternoon Market Update: Markets All Green, Research in Motion Looks to Test High 17's

Financial news for IPXL dated on 2013-01-22: Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

Financial news for IPXL dated on 2013-01-22: Impax Labs Shares Down Sharply After FDA CRL for RYTARY NDA; Canaccord Says Buy the Dip

Financial news for IPXL dated on 2013-01-04: Impax Labs Launches Oxymorphone Hydrochloride ER Tablets

Financial news for IPXL dated on 2013-01-04: Impax Commences Shipment of Oxymorphone Hydrochloride Extended-Release Tablets

Financial news for IPXL dated on 2012-12-28: UPDATE: J.P. Morgan Reiterates Neutral Rating, Lowers PT on Impax Laboratories

Financial news for IPXL dated on 2012-12-13: Impax Labs Names Bryan Reasons CFO

Financial news for IPXL dated on 2012-11-21: Impax Labs Enters Commercialization Deal with Perrigo

Financial news for IPXL dated on 2012-11-16: Impax Labs, ThoRx Confirm Opana Patent Challenge

Financial news for IPXL dated on 2012-10-31: UPDATE: Goldman Sachs Lowers PT to \$22 on Impax Laboratories on Competitive Risks

Financial news for IPXL dated on 2012-10-31: Goldman Sachs Maintains Impax Laboratories at Sell, Lowers PT from \$24 to \$22

Financial news for IPXL dated on 2012-10-30: Impax Laboratories Reports Q3 EPS \$0.48 vs \$0.49 Est; Revenues \$145.58M vs \$164.42M Est

Financial news for IPXL dated on 2012-10-12: Impax Pharmaceuticals Announces Extension of RytaryTM FDA Review Date to January 21, 201

Financial news for IPXL dated on 2012-10-08: Impax Labs Sued by Avanir Over Neurological Patent -Bloomberg

Financial news for IPXL dated on 2012-10-05: UPDATE: Bank of America Merrill Lynch Reiterates Underperform Rating, Raises PO on Impax Laboratories

Financial news for IPXL dated on 2012-10-05: Bank of America Maintains Impax Laboratories at Underperform, Raises PO from \$22 to \$25

Financial news for IPXL dated on 2012-10-03: UPDATE: Goldman Sachs Reiterates Sell Rating, Raises PT on Impax Laboratories

Financial news for IPXL dated on 2012-10-03: Goldman Sachs Maintains Impax Laboratories at Sell, Raises PT from \$19 to \$24

Financial news for IPXL dated on 2012-09-14: Impax Labs Announces Settlement of Litigation with Janssen

Financial news for IPXL dated on 2012-08-01: Jefferies & Company Maintains Impax Laboratories at Hold, Raises PT from \$20 to \$21

Financial news for IPXL dated on 2012-07-31: Impax Laboratories Reports Q2 EPS \$0.60 vs \$0.44 Est; Revenues \$166.5M vs \$162.03M Est

Financial news for IPXL dated on 2012-07-06: UPDATE: Goldman Sachs Trims EPS Estimates for Impax Laboratories, Lowers PT

Financial news for IPXL dated on 2012-07-06: Goldman Sachs Lowers PT on Impax Laboratories from \$20 to \$19

Financial news for IPXL dated on 2012-07-02: Piper Jaffray Maintains Impax Laboratories at Overweight, Lowers PT from \$32 to \$30

Financial news for IPXL dated on 2012-06-29: Impax Labs CFO Resigns

Financial news for IPXL dated on 2012-06-25: UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT for Impax Laboratories

Financial news for IPXL dated on 2012-06-25: Bank of America Merrill Lynch Reiterates Underperform Rating, \$22 PT for Impax Laboratories

Financial news for IPXL dated on 2012-06-25: Jefferies & Company Maintains Impax Laboratories at Hold, Lowers PT from \$21 to \$20

Financial news for IPXL dated on 2012-05-23: Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin

Financial news for IPXL dated on 2012-05-08: Impax Gets Civil Investigative Demand from FTC, Says CID Concerning Investigation Into Solodyn and Generics; FTC Probing Possible Unfair Competition Methods; MRX and 6 Other Companies Being Investigated

Financial news for IPXL dated on 2012-05-01: Impax Laboratories Reports Q1 EPS \$0.52 vs \$0.47 Est; Revenues \$128.6M May Not Compare vs \$162.79M Est

Financial news for IPXL dated on 2012-04-18: Data from ASCEND-PD Phase III Study of IPX066 to be Presented at the American Academy of Neurology Conference

Financial news for IPXL dated on 2012-04-12: Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISE(r) 300 mg and 600 mg

Financial news for IPXL dated on 2012-04-10: UBS Maintains Impax Laboratories at Neutral, Raises PT from \$24 to \$26

Financial news for IPXL dated on 2012-03-26: Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR

Financial news for IPXL dated on 2012-03-02: Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue

Financial news for IPXL dated on 2012-02-29: UBS Maintains Impax Laboratories at Neutral, Raises PT from \$21 to \$24

Financial news for IPXL dated on 2012-02-29: Jefferies & Company Maintains Impax Laboratories at Hold, Raises PT from \$17 to \$21

Financial news for IPXL dated on 2012-02-28: Earnings Roundup

Financial news for IPXL dated on 2012-02-28: UPDATE: Impax Laboratories Q4 Net Profit Jumps 76%

Financial news for IPXL dated on 2012-02-28: Financial Breakfast: Morning News Summary for February 28, 2012

Financial news for IPXL dated on 2012-02-28: Impax Laboratories Reports Q4 EPS \$0.33 vs \$0.22 Est; Revenues \$158.56M vs \$128.51M Est

Financial news for IPXL dated on 2012-02-23: Financial Breakfast: Morning News Summary for February 23, 2012

Financial news for IPXL dated on 2012-02-23: FDA Accepts Impax Pharmaceuticals NDA Filing for IPX066 for the Treatment of Idiopathic Parkinson's Disease

Financial news for IPXL dated on 2012-02-09: A Peek Into The Market Before The Trading Starts

Financial news for IPXL dated on 2012-02-09: Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility

Financial news for IPXL dated on 2012-02-08: Hearing Court Likely to Issue Decision in Favor of Mylan and Impax; Warner Chilcott Spikes Lower

Financial news for IPXL dated on 2012-02-01: Impax Laboratories Resumes Trading

Financial news for IPXL dated on 2012-02-01: UPDATE: Impax to Pay \$130M; to Get Benefit of Gross Profit Beginning from Jan 1, 2012

Financial news for IPXL dated on 2012-02-01: Impax Pharmaceuticals Licenses Exclusive U.S. Commercialization Rights to Zomig from AstraZeneca

Financial news for IPXL dated on 2012-02-01: Trading Halted in Impax Labs, News Pending

Financial news for IPXL dated on 2012-01-23: Perrigo Confirms Filing for Generic Version of Astepro(r) Nasal Spray; Patent Infringement Lawsuit by Meda Pharmaceuticals

Financial news for IPXL dated on 2012-01-11: Piper Jaffray Reiterates Overweight Rating on Impax Labs

Financial news for IPXL dated on 2012-01-09: Canaccord Upgrades Impax Laboratories to Buy

Financial news for IPXL dated on 2011-12-29: Impax Laboratories Spiking Higher on Heavy Volume

Financial news for IPXL dated on 2011-12-21: Impax Pharmaceuticals Submits New Drug Application for IPX066 in Parkinson's Disease

Financial news for IPXL dated on 2011-12-19: Impax Pharmaceuticals Initiates Phase IIb Trial of IPX159 in Restless Legs Syndrome

Financial news for IPXL dated on 2011-12-01: Piper Jaffray Maintains Overweight

Rating and \$32 PT on Impax Laboratories

Financial news for IPXL dated on 2011-11-21: Impax Laboratories Confirms Patent Challenge Relating to Generic FENTORA

Financial news for IPXL dated on 2011-11-01: Impax Laboratories Reports Q EPS \$0.30 vs \$0.23 Est; Revenues \$119.8M vs \$128.17M Est

Financial news for IPXL dated on 2011-10-21: Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue

Financial news for IPXL dated on 2011-10-18: Perrigo Confirms Filing for Generic Version of PATANASE(r) Nasal Spray and Announcement of Patent Infringement Lawsuit by Alcon Laboratories

Financial news for IPXL dated on 2011-10-13: Forest Laboratories Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for IPXL dated on 2011-09-28: Hearing MYL, PRGO, IPXL Initiated at Hold by Canaccord

Financial news for IPXL dated on 2011-09-22: Goldman Sachs Downgrades Impax Laboratories to Sell

Financial news for IPXL dated on 2011-09-12: Impax Laboratories Confirms Patent Challenge Relating to Generic JALYN 0.5 mg/0.4 mg

Financial news for IPXL dated on 2011-08-31: Impax Laboratories Confirms Patent Challenge Relating to Generic NUEDEXTA(r) 20 mg/10 mg

Financial news for IPXL dated on 2011-08-15: Benzinga's Volume Movers

Financial news for IPXL dated on 2011-08-15: Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson's Disease

Financial news for IPXL dated on 2011-08-08: J.P. Morgan Maintains Neutral on Impax Laboratories

Financial news for IPXL dated on 2011-08-04: Goldman Sachs Updates EPS Estimates On Impax

Financial news for IPXL dated on 2011-08-04: Goldman Sachs Lowers PT On Impax Laboratories To \$25

Financial news for IPXL dated on 2011-08-03: UPDATE: Piper Jaffray Lowering Price Target On Impax Laboratories

Financial news for IPXL dated on 2011-08-03: Piper Jaffray Lowers PT On Impax Laboratories To \$32

Financial news for IPXL dated on 2011-08-02: J.P. Morgan Neutral On Impax Laboratories

Financial news for IPXL dated on 2011-08-02: Impax Laboratories Reports Q EPS \$0.22 vs \$0.19 Est; Revenues \$125.9M vs \$110.94M Est

Financial news for IPXL dated on 2011-07-27: Piper Jaffray Comments On Impax

Financial news for IPXL dated on 2011-07-26: Impax Pharmaceuticals Completes Enrollment in ASCEND-PD Phase III Trial of IPX066 in Parkinson's Disease

Financial news for IPXL dated on 2011-07-13: Piper Jaffray Reiterates Overweight and Pt of \$33 on Impax Laboratories

Financial news for IPXL dated on 2011-06-30: Impax Laboratories Announces Settlement of Litigation Relating to WELCHOL(r) Tablets and WELCHOL(r) Oral Suspension Products

Financial news for IPXL dated on 2011-06-09: Piper Jaffray Comments On Strong Long-Term Fundamentals for Impax

Financial news for IPXL dated on 2011-06-08: Top Percentage Gainers and Losers as of 2pm 06/08/11

Financial news for IPXL dated on 2011-06-08: Top Percentage Gainers and Losers as of 12pm 06/08/11

Financial news for IPXL dated on 2011-06-08: Benzinga's Top Downgrades

Financial news for IPXL dated on 2011-06-08: J.P. Morgan Downgrades Rating, Lowers PT

To \$26 On IPXL

Financial news for IPXL dated on 2011-06-08: JP Morgan Downgrades Impax Laboratories To Neutral, Lowers PT To \$26

Financial news for IPXL dated on 2011-06-06: Impax Laboratories Resumes Trading

Financial news for IPXL dated on 2011-06-06: Impax Laboratories Provides an Update on Recent FDA Site Inspection

Financial news for IPXL dated on 2011-06-03: Impax Laboratories Confirms Patent Suit Relating to Generic Detrol Immediate-Release 1 mg and 2 mg Tablets

Financial news for IPXL dated on 2011-06-03: Piper Jaffray Overweight On Impax Laboratories

Financial news for IPXL dated on 2011-05-20: Piper Jaffray Comments On Impax Estimates

Financial news for IPXL dated on 2011-05-04: Piper Jaffray Raises PT On IPXL To \$33

Financial news for IPXL dated on 2011-05-04: Piper Jaffray Raises PT On Impax Laboratories To \$33

Financial news for IPXL dated on 2011-05-03: Impax Laboratories Reports Q1 EPS of \$0.21 vs. \$0.15 Estimate; Revenues \$108.7M vs. \$101.21M Estimate (IPXL)

Financial news for IPXL dated on 2011-04-15: Piper Jaffray Reiterating Overweight On Impax Laboratories (IPXL)

Financial news for IPXL dated on 2011-04-11: Impax Lab Confirms a Patent Challenge Relating to Oxycontin (IPXL)

Financial news for IPXL dated on 2011-04-11: Impax Laboratories Confirms Patent Challenge Relating to OXYCONTIN

Financial news for IPXL dated on 2011-04-08: Impax Labs In Commercialization Agreement With Banner (IPXL)

Financial news for IPXL dated on 2011-04-04: Impax Laboratories Confirms Patent Challenge Relating to DEXILANT Delayed-Release Capsules

Financial news for IPXL dated on 2011-04-01: Impax Laboratories Announces That Data on IPX066 APEX-PD Phase III Study for the Treatment of Early Parkinson's Disease to be Presented at the American Academy of Neurology Conference

Financial news for IPXL dated on 2011-03-31: Piper Jaffray Reiterating Overweight On Impax Laboratories (IPXL)

Financial news for IPXL dated on 2011-03-25: Piper Jaffray Reiterates OW Rating, \$30 PT On IPXL

Financial news for IPXL dated on 2011-03-15: Benzinga's Volume Movers (IPXL, FSLR, SPWRA, NFLX)

Financial news for IPXL dated on 2011-03-15: J.P. Morgan Maintains Overweight on Impax Laboratories (IPXL)

Financial news for IPXL dated on 2011-03-15: Impax Reports Positive Phase III Results, Goldman Maintains Neutral Rating

Financial news for IPXL dated on 2011-03-15: Piper Jaffray Reiterates Overweight on Impax Laboratories (IPXL)

Financial news for IPXL dated on 2011-02-28: J.P. Morgan Refining Model For Impax Laboratories Following 10-K

Financial news for IPXL dated on 2011-02-18: Impax Laboratories Receives Final FDA Approval for Generic Adoxa 150 mg Capsules

Financial news for IPXL dated on 2011-01-20: Piper Jaffray Reiterates Overweight Rating, \$27 PT On IPXL

Financial news for IPXL dated on 2011-01-13: Best Biotech Stocks To Own Now (CRIS, CGEN, SPPI, IPXL)

Financial news for IPXL dated on 2011-01-12: Piper Jaffray Reiterates Overweight On Impax Laboratories (IPXL)

Financial news for IPXL dated on 2011-01-05: Piper Jaffray Raises IPXL Target To \$27 From \$25

Financial news for IPXL dated on 2011-01-05: Piper Jaffray Raises PT On Impax Laboratories

Financial news for IPXL dated on 2010-12-30: East West Bancorp: Premarket Trading

Financial news for IPXL dated on 2010-12-29: Impax Laboratories Not Moving Much Despite FDA Approval (IPXL)

Financial news for IPXL dated on 2010-12-29: Impax Laboratories Up On FDA Approval (IPXL)

Financial news for IPXL dated on 2010-12-29: Impax Laboratories Receives Final FDA Approval for Generic Doryx

Financial news for IPXL dated on 2010-12-16: Impax Laboratories Up 6.4% After Deal With GlaxoSmithKline (IPXL, GSK)

Financial news for IPXL dated on 2010-12-02: Piper Jaffray Reiterates Overweight Rating on Impax Laboratories (IPXL)

Financial news for IPXL dated on 2010-11-29: Impax Laboratories Confirms Patent Suit Relating to Generic Concerta

Financial news for IPXL dated on 2010-11-29: Impax Laboratories Confirms Patent Suit Relating to Generic Concerta

Financial news for IPXL dated on 2010-11-26: Impax Laboratories Confirms Patent Challenge Relating to SIMCOR

Financial news for IPXL dated on 2010-11-22: Positive Data on Merck's Vytorin - Analyst Blog

Financial news for IPXL dated on 2010-11-22: Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta

Financial news for IPXL dated on 2010-11-22: Positive Data on Merck's Vytorin - Analyst Blog

Financial news for IPXL dated on 2010-11-11: Zacks #5 Rank Additions for Thursday - Tale of the Tape

Financial news for IPXL dated on 2010-10-21: Zacks Sell List Highlights: MTN,PSS,DVA,IPXL - Press Releases

Financial news for IPXL dated on 2010-09-24: Piper Jaffray Overweight On Impax Laboratories (IPXL)

Financial news for IPXL dated on 2010-08-31: New Dosages of Solodyn Approved - Analyst Blog

Financial news for IPXL dated on 2010-08-19: FDA to Withdraw Shire Drug Approval - Analyst Blog

Financial news for IPXL dated on 2010-08-17: Impax Laboratories Director Buys 46,200 Shares of IPXL

Financial news for IPXL dated on 2010-07-22: Impax Laboratories Receives Final FDA Approval for Generic OPANA(r) ER Tablets

Financial news for IPXL dated on 2010-07-20: Jefferies & Co.'s Weekly Rx Update (FRX, MRX, IPXL)

Financial news for IPXL dated on 2010-07-19: Piper Jaffray Reiterates Overweight Rating on Impax Laboratories (IPXL)

Financial news for IPXL dated on 2010-07-06: Impax Weakness Overblown, Cash Still Flowing; Piper Jaffray (IPXL)

Financial news for IPXL dated on 2010-07-06: Generics Bill Passes House, Faces Senate Roadblock, Says Jefferies (TEVA, IPXL, CEPH)

Financial news for IPXL dated on 2010-07-02: Impax Laboratories Confirms Patent Challenge Relating to A Genzyme Product

Financial news for IPXL dated on 2010-06-21: Stocks Hitting 52-Week Highs (AIPC, CRUS, HMIN, IPXL)

Financial news for IPXL dated on 2010-06-09: With the Market Tanking, Why are These Three Stocks Up?

Financial news for IPXL dated on 2010-06-09: Impax Laboratories Settles Lawsuit, Impacts Price Target

Financial news for IPXL dated on 2010-06-07: Impax Laboratories (IPXL) Gets 'Overweight' Rating

Financial news for IPXL dated on 2010-06-02: Benzinga's Top Downgrades (RL, EXC, CA, IPXL, THC)

Financial news for IPXL dated on 2010-06-02: IPXL Downgraded To Market Perform At Wells Fargo

Financial news for IPXL dated on 2010-05-27: Stocks That Crossed 52-Week Highs (CPBC, IPXL, NTAP, SPRD)

Financial news for IPXL dated on 2010-05-20: IPXL: Most Attractive Generics Opportunity

Financial news for IPXL dated on 2010-05-19: Stocks That Crossed 52-Week Highs (BRID, IPXL, QSFT, RADS)

Financial news for IPXL dated on 2010-05-13: Stocks That Crossed 52-Week Highs (IPXL, INTT, IIN, IRBT)

Financial news for IPXL dated on 2010-05-05: IPXL Posts Solid Q1 On Flomax Performance

Financial news for IPXL dated on 2010-05-04: Stocks That Crossed 52-Week Highs (AKRX, CGNX, DMLP, IPXL, INHX)

Financial news for IPXL dated on 2010-05-04: Benzinga's Top Pre-Market Gainers (MSON, NTRI, PWAV, IPXL, LLEN)

Financial news for IPXL dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for IPXL dated on 2010-02-25: Stocks That Created New 52-Week Highs (IPXL, LCAPA, NEWS, NEWT, NXTM)

Financial news for IPXL dated on 2010-02-25: Benzinga's Top Pre-Market Gainers (BVF, PCS, MYL, ESRX, IPXL)

Financial news for IPXL dated on 2010-02-25: IPXL Posts 294% Jump In Q4 Revenues